Shortwave Life Sciences' Psilocybin Combination Shows Positive Pre-Clinical Safety Results for Anorexia Treatment
Key Insights
Shortwave Life Sciences (search) reports positive pre-clinical safety results for its psilocybin-based combination drug aimed at treating anorexia nervosa (search).
The study, conducted with Science in Action, showed no adverse effects in rats at elevated doses of the drug administered buccally.
This milestone supports Shortwave's advancement towards human trials and validates its patent-pending buccal delivery system for mental health treatments.
Shortwave Life Sciences (search) has announced positive pre-clinical safety results for its proprietary psilocybin-based combination drug, marking a significant step toward human trials for the treatment of anorexia. The study, conducted in collaboration with Science in Action, demonstrated the safety of the drug combination at elevated doses when administered buccally.
The pre-clinical pharmacodynamics study involved administering varying doses (0.23ml, 0.5ml, and 1ml) of Shortwave's combination drug to three groups of rats. The results indicated no adverse effects, weight changes, or behavioral changes following the psychedelic effects. According to the company, all subjects remained healthy throughout the trial, providing a strong foundation for clinical development.
Key Findings from the Pre-Clinical Study
- No adverse events or vital sign changes were reported across all groups.
- The safety profile of the psilocybin-based combination drug was confirmed at elevated doses.
- The study reaffirmed the efficiency of Shortwave's buccal delivery platform.
Rivki Stern Youdkevich, CEO of Shortwave, stated, "This is a monumental step forward for Shortwave... We are proud of the positive outcomes from this rigorous pre-clinical trial, further validating our patent-pending drug combination and buccal delivery system."
This achievement follows the International PCT Examining Committee's acknowledgement of Shortwave's patent claims for its mucoadhesive buccal film. The platform is designed for rapid absorption, bypassing liver and gut degradation, and holds potential for patients facing metabolic and psychiatric challenges.
Addressing Unmet Needs in Mental Health
Shortwave Life Sciences (search) is focused on developing therapies for unmet medical needs in mental health. The company's approach involves drug development and aims to introduce solutions for mental health disorders worldwide. The positive pre-clinical results drive Shortwave closer to human trials, with the goal of reshaping the mental health treatment landscape, particularly in the field of eating disorders.